We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck’s blockbuster drug Keytruda (pembrolizumab) may be approved to treat 17 different kinds of cancer, but the monoclonal antibody doesn’t always hit it out of the park. Read More
Last week’s Paris meeting of the European Society of Medical Oncology (ESMO) featured a hit and a miss in renal cell cancer and some good news for elderly patients who can’t take platinum-based chemo regimens for non-small cell lung cancer (NSCL). Read More
Regeneron and Bayer’s blockbuster Eylea (aflibercept) given in three- or four-month intervals demonstrated efficacy against two major eye diseases in a pair of late-stage studies, giving the drugmakers an edge in an increasingly competitive market. Read More
In its 2022 Focus Areas of Regulatory Science report released last week, the FDA adds to its list of regulatory priorities research efforts in oncology and rare disease. Read More
Roche is acquiring Good Therapeutics for $250 million in upfront cash, gaining Good’s conditionally active biologics (CAB) to create new immunotherapies for treating cancer. Read More
In just six pages of final guidance released today, the FDA lays out exactly when and how sponsors should include real-world data and real-world evidence (RWD/RWE) in applications for investigational and new drugs, as well as biologics licenses. Read More
Two late-breaking phase 3 studies highlighted advances in breast and colorectal cancer at the annual meeting of the European Society of Medical Oncology in Paris this week. Read More